

SEARCHED

03 MAY 2005

PATENT COOPERATION TREATY

PCT

REC'D 11 MAY 2005

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

WIPO

PCT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference TEX4542P04	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US03/35526	International filing date (day/month/year) 07 November 2003 (07.11.2003)	Priority date (day/month/year) 08 November 2002 (08.11.2002)
International Patent Classification (IPC) or national classification and IPC IPC(7): C07D 239/47, 213/75, 237/22, 215/38, 498/04; A61K 31/505, 31/44, 31/50 and US Cl.: 546/155, 183, 296, 297; 544/319; 514/269, 299, 312, 348, 349		
Applicant ENCYSIVE PHARMACEUTICALS, INC.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 3 sheets, including this cover sheet.

This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of ___ sheets.

3. This report contains indications relating to the following items:

- I Basis of the report
- II Priority
- III Non-establishment of report with regard to novelty, inventive step and industrial applicability
- IV Lack of unity of invention
- V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI Certain documents cited
- VII Certain defects in the international application
- VIII Certain observations on the international application

Date of submission of the demand 07 June 2004 (07.06.2004)	Date of completion of this report 14 April 2005 (14.04.2005)
Name and mailing address of the IPEA/US Mail Stop PCT, Attn: IPEA/ US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230	Authorized officer Deepak Rao Telephone No. 571-272-1600 <i>Janice Ford</i> <i>for</i>

Form PCT/IPEA/409 (cover sheet)(July 1998)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US03/35526

I. Basis of the report

1. With regard to the elements of the international application:*

the international application as originally filed.

the description:
pages 1-33 as originally filed
pages NONE, filed with the demand
pages NONE, filed with the letter of _____

the claims:
pages 34-51 as originally filed
pages NONE, as amended (together with any statement) under Article 19
pages NONE, filed with the demand
pages NONE, filed with the letter of _____

the drawings:
pages NONE, as originally filed
pages NONE, filed with the demand
pages NONE, filed with the letter of _____

the sequence listing part of the description:
pages NONE, as originally filed
pages NONE, filed with the demand
pages NONE, filed with the letter of _____

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language _____ which is:

the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).

the language of publication of the international application (under Rule 48.3(b)).

the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing.

contained in the international application in printed form.

filed together with the international application in computer readable form.

furnished subsequently to this Authority in written form.

furnished subsequently to this Authority in computer readable form.

The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

the description, pages NONE

the claims, Nos. NONE

the drawings, sheets/fig NONE

5. This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

* INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/US03/35526

V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. STATEMENT

Novelty (N)	Claims <u>19</u>	YES
	Claims <u>1-18 and 20-26</u>	NO

Inventive Step (IS)	Claims <u>NONE</u>	YES
	Claims <u>1-26</u>	NO

Industrial Applicability (IA)	Claims <u>1-26</u>	YES
	Claims <u>NONE</u>	NO

2. CITATIONS AND EXPLANATIONS

Claims 1-18 and 20-26 lack novelty under PCT Article 33(2) as being anticipated by EP 1203766. The reference teaches compounds and compositions that are useful in pharmaceutical therapeutic applications, see the structural formula (I) in page 3 and the corresponding examples.

Claims 1-26 lack an inventive step under PCT Article 33(3) as being obvious over EP 1203766. The reference teaches compounds of formula I, and the corresponding compositions comprising one or more active ingredients. The compounds are disclosed to be useful as pharmaceutical therapeutic agents in the treatment of diseases such as atherosclerosis, rheumatoid arthritis, etc., see page 44. The instant claims differ by having a second therapeutic compound, which according to the disclosure is a known pharmaceutical therapeutic agent for treating an inflammatory disease, etc. One having ordinary skill in the art would have been motivated to combine the reference disclosed compounds with other known therapeutic compounds with the reasonable expectation that the combination would have the same properties and therefore, the same use as taught for the individual ingredients.

Claims 19 meets the criteria of novelty set out in PCT Article 33(2), because the prior art does not teach or fairly suggest the instantly recited second therapeutic compounds, see EP 1203766.

Claims 1-26 meet the criteria set out in PCT Article 33(4), because the compounds are disclosed to be useful as herbicidal agents, and thus meet the criteria of industrial applicability because the subject matter claimed can be made or used in industry.